MedTrace Logo

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT03215030 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The main aims of this 3-part study are as follows:

Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found.

Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants.

Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa.

Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

Conditions

Interventions

DRUG

Dexamethasone

Dexamethasone.

DRUG

Modakafusp alfa

Modakafusp alfa intravenous infusion.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-04
Primary Completion
2024-07-01
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Japan
  • Norway
  • Puerto Rico
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03215030 on ClinicalTrials.gov